BTVPUR Alsap 8

RSS
Withdrawn

This medicine's authorisation has been withdrawn

adjuvanted bluetongue virus vaccine
MedicineVeterinaryWithdrawn
  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for BTVPUR AlSap 8 has been withdrawn at the request of the marketing-authorisation holder.

български (BG) (276.19 KB - PDF)

View

español (ES) (214.85 KB - PDF)

View

čeština (CS) (282.09 KB - PDF)

View

dansk (DA) (238.31 KB - PDF)

View

Deutsch (DE) (217.39 KB - PDF)

View

eesti keel (ET) (214.24 KB - PDF)

View

ελληνικά (EL) (304.53 KB - PDF)

View

français (FR) (239.03 KB - PDF)

View

italiano (IT) (215.73 KB - PDF)

View

latviešu valoda (LV) (94.58 KB - PDF)

View

lietuvių kalba (LT) (119.27 KB - PDF)

View

magyar (HU) (257.98 KB - PDF)

View

Malti (MT) (122.68 KB - PDF)

View

Nederlands (NL) (71.87 KB - PDF)

View

polski (PL) (100.02 KB - PDF)

View

português (PT) (71.88 KB - PDF)

View

română (RO) (118.17 KB - PDF)

View

slovenčina (SK) (120.6 KB - PDF)

View

slovenščina (SL) (110.34 KB - PDF)

View

Suomi (FI) (216.27 KB - PDF)

View

svenska (SV) (71.75 KB - PDF)

View

Product information

български (BG) (743.97 KB - PDF)

View

español (ES) (471.21 KB - PDF)

View

čeština (CS) (625.92 KB - PDF)

View

dansk (DA) (404.57 KB - PDF)

View

Deutsch (DE) (481.49 KB - PDF)

View

eesti keel (ET) (481.1 KB - PDF)

View

ελληνικά (EL) (760 KB - PDF)

View

français (FR) (417.92 KB - PDF)

View

hrvatski (HR) (521.62 KB - PDF)

View

íslenska (IS) (401.48 KB - PDF)

View

italiano (IT) (414.09 KB - PDF)

View

latviešu valoda (LV) (649.44 KB - PDF)

View

lietuvių kalba (LT) (540.05 KB - PDF)

View

magyar (HU) (652.27 KB - PDF)

View

Malti (MT) (653.21 KB - PDF)

View

Nederlands (NL) (474.89 KB - PDF)

View

norsk (NO) (402.13 KB - PDF)

View

polski (PL) (661.05 KB - PDF)

View

português (PT) (476.05 KB - PDF)

View

română (RO) (543.38 KB - PDF)

View

slovenčina (SK) (663.03 KB - PDF)

View

slovenščina (SL) (624.08 KB - PDF)

View

Suomi (FI) (407.04 KB - PDF)

View

svenska (SV) (406.34 KB - PDF)

View
Latest procedure affecting product information: R/0010
13/03/2014

български (BG) (241.84 KB - PDF)

View

español (ES) (177.73 KB - PDF)

View

čeština (CS) (211.31 KB - PDF)

View

dansk (DA) (164.97 KB - PDF)

View

Deutsch (DE) (173.27 KB - PDF)

View

eesti keel (ET) (172.66 KB - PDF)

View

ελληνικά (EL) (237.8 KB - PDF)

View

français (FR) (165.01 KB - PDF)

View

íslenska (IS) (166.62 KB - PDF)

View

italiano (IT) (166.47 KB - PDF)

View

latviešu valoda (LV) (214.89 KB - PDF)

View

lietuvių kalba (LT) (212.85 KB - PDF)

View

magyar (HU) (204.67 KB - PDF)

View

Malti (MT) (225.73 KB - PDF)

View

Nederlands (NL) (172.82 KB - PDF)

View

norsk (NO) (164.38 KB - PDF)

View

polski (PL) (236.78 KB - PDF)

View

português (PT) (176.81 KB - PDF)

View

română (RO) (210.41 KB - PDF)

View

slovenčina (SK) (210.94 KB - PDF)

View

slovenščina (SL) (209.82 KB - PDF)

View

Suomi (FI) (173.21 KB - PDF)

View

svenska (SV) (165.48 KB - PDF)

View

Product details

Name of medicine
BTVPUR Alsap 8
Active substance
bluetongue virus serotype 8 antigen
International non-proprietary name (INN) or common name
adjuvanted bluetongue virus vaccine
Species
  • Sheep
  • Cattle
Anatomical therapeutic chemical veterinary (ATCvet) code
QI02AA08

Pharmacotherapeutic group

  • Immunologicals for Ovidae
  • Immunologicals for Bovidae

Therapeutic indication

Active immunisation of sheep and cattle to prevent viraemia* and to reduce clinical signs caused by bluetongue virus serotype 8.
*(below the level of detection by the validated RT-PCR method at 3.14log10 RNA copies/ml, indicating no infectious virus transmission).

Onset of immunity has been demonstrated 3 weeks after the primary vaccination course.

The duration of immunity for cattle and sheep is 1 year after the primary vaccination course.

The duration of immunity is not yet fully established in cattle or sheep, although interim results of ongoing studies demonstrate that the duration is at least 6 months after the primary vaccination course in sheep.

Authorisation details

EMA product number
EMEA/V/C/000146
Marketing authorisation holder
Merial

29 Avenue Tony Garnier
69007 Lyon
France

Marketing authorisation issued
17/03/2009
Revision
5

Assessment history

This page was last updated on

Share this page